A European Collaborative Project within Health Research, funded with the support of the Seventh Framework Programme (FP7) and coordinated by the Department of Physics, University of Oslo, Norway
Solid cancers generally contain areas with abnormally low levels of oxygen. Such areas are denoted hypoxic.
It has long been known that cancer cells in such hypoxic micro-environments are resistant to treatment.
Recent research has shown that hypoxia in tumours is one of the major drivers of metastatic spread of cancer, the major cause of death by the disease.
Thus, hypoxia is responsible for a double effect of reducing the potential of a successful treatment of the cancer patient: Resistance to treatment and ability to spread. At the same time the very low level of oxygen found in solid tumours are specific to cancer.
Therefore, if one could develop methods that specifically located and inactivated cells in hypoxic areas one might obtain a cancer-specific effect, selective for the most harmful of the cancer cells.
This development is the core task of the METOXIA project.
METOXIA – et Kinderegg for kreftbehandling
Jan. 15, 2016 3:06 PM
Ny kunnskap om kreftceller i oksygenfattig miljø, ny metode som hindrer spredning av kreft samt innovasjon. Det gigantiske UiO-styrte EU-prosjektet METOXIA er et som et Kinderegg; flere godbiter i ett.
Forging new paths in pursuit of more targeted cancer treatments
June 22, 2015 1:20 PM
EU-funded researchers have developed an innovative new cancer treatment. Interest from the pharmaceutical industry has been so great that the research team has set up a company dedicated to bringing their innovations to market.
Oct. 23, 2014 10:59 AM
A total of 448 publications with acknowledgement to the METOXIA project, by project partners, have been listed in the EUs Participant Portal for the period 2009 - 2014. A list of the publications is now available on the website under About METOXIA-Publications.
Scientific developments of METOXIA
Oct. 21, 2014 5:01 PM
The METOXIA project was in operation from February 2009 until July 2014. It is officially finished as an EU-funded project, nevertheless important and related research will continue with the partners of MEOXIA, and new EU-funded projects may in the future be created with partners from the METOXIA group.
For information on the outcome of the project see METOXIA final summary of main findings and results